Details for Patent: 10,385,078
✉ Email this page to a colleague
Which drugs does patent 10,385,078 protect, and when does it expire?
Patent 10,385,078 protects ALUNBRIG and is included in one NDA.
This patent has forty patent family members in thirty-one countries.
Summary for Patent: 10,385,078
| Title: | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylp- iperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
| Abstract: | Crystalline forms of brigatinib, pharmaceutical compositions comprising the same, and methods of their preparation and use of the same are disclosed herein. |
| Inventor(s): | Rozamus; Leonard W. (Andover, MA), Sharma; Pradeep (Westford, MA) |
| Assignee: | ARIAD PHARMACEUTICALS, INC. (Cambridge, MA) |
| Application Number: | 15/520,694 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 10,385,078
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ⤷ Try a Trial | ||
| Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-002 | Apr 28, 2017 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ⤷ Try a Trial | ||
| Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 10,385,078
| PCT Information | |||
| PCT Filed | October 21, 2015 | PCT Application Number: | PCT/US2015/056701 |
| PCT Publication Date: | April 28, 2016 | PCT Publication Number: | WO2016/065028 |
International Family Members for US Patent 10,385,078
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2015335950 | ⤷ Try a Trial | |||
| Canada | 2965169 | ⤷ Try a Trial | |||
| Chile | 2017000979 | ⤷ Try a Trial | |||
| China | 107108559 | ⤷ Try a Trial | |||
| China | 111825717 | ⤷ Try a Trial | |||
| China | 111888368 | ⤷ Try a Trial | |||
| Colombia | 2017004714 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
